Table 2.

Saccade characteristics of controls and patients with schizophrenia^*

	Group; mean ± SD		Patient subgroup; mean ± SD
Characteristic	Controls, n = 29	Schizophrenia, n = 38†	Antipsychoticfree, n = 13	Clozapine, n = 10	Haloperidol, n = 15†
Peak velocity, º/s	634.0 ± 82.5	602.1 ± 114.1	615.3 ± 93.2	643.8 ± 86.9	562.0 ± 137.7
Duration, ms	88.2 ± 17.3	91.3 ± 18.0	91.9 ± 14.2	83.9 ± 7.0	96.1 ± 24.3
Pregain	0.93 ± 0.04	0.91 ± 0.05	0.93 ± 0.06	0.91 ± 0.04	0.89 ± 0.05
Postgain	0.75 ± 0.05	0.73 ± 0.06	0.73 ± 0.06	0.76 ± 0.05	0.71 ± 0.06

SD = standard deviation.

^*No differences in basic saccade characteristics (peak velocity, duration, gains) were found among any of the groups. Saccade gains (defined as saccade amplitude/target amplitude) were calculated at baseline (pregain) and after saccade adaptation (postgain) and did not differ significantly between controls and patients with schizophrenia (Student t tests) or among patient subgroups (univariate analyses of variance).

^†Not significant.